CPI-444

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) nearly half its value Tuesday following the release of interim results of its Phase 1 study of CPI-444, designed to treat patients with advanced cancers. Cantor Fitzgerald believes the selloff is understandable, but feel it has been overdone. The firm...